These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 380688)
1. Diminished platelet adenylate cyclase activation by prostaglandin D2 in acute thrombosis. Cooper B Blood; 1979 Sep; 54(3):684-93. PubMed ID: 380688 [TBL] [Abstract][Full Text] [Related]
2. Desensitization of prostaglandin-activated platelet adenylate cyclase. Cooper B; Schafer AI; Puchalsky D; Handin RI Prostaglandins; 1979 Apr; 17(4):561-71. PubMed ID: 461820 [TBL] [Abstract][Full Text] [Related]
3. The antagonism of prostaglandins I2, E1 and D2 by prostaglandin E2 in human platelets. Bonne C; Martin B; Watada M; Regnault F Thromb Res; 1981 Jan 1-15; 21(1-2):13-22. PubMed ID: 6262942 [No Abstract] [Full Text] [Related]
4. Inhibition of adenylate cyclase by adenosine analogues in preparations of broken and intact human platelets. Evidence for the unidirectional control of platelet function by cyclic AMP. Haslam RJ; Davidson MM; Desjardins JV Biochem J; 1978 Oct; 176(1):83-95. PubMed ID: 215136 [TBL] [Abstract][Full Text] [Related]
5. The antagonism by BW A868C of PGD2 and BW245C activation of human platelet adenylate cyclase. Trist DG; Collins BA; Wood J; Kelly MG; Robertson AD Br J Pharmacol; 1989 Feb; 96(2):301-6. PubMed ID: 2466517 [TBL] [Abstract][Full Text] [Related]
6. Cytochemical localization of adenylate cyclase in the dense tubule system of human blood platelets stimulated by forskolin, prostacyclin and prostaglandin D2. Cutler LS; Christian CP; Feinstein MB Biochim Biophys Acta; 1985 Jun; 845(3):403-10. PubMed ID: 3890960 [TBL] [Abstract][Full Text] [Related]
7. Comparison of the effects of prostacyclin (PGI2), prostaglandin E1 and D2 on platelet aggregation in different species. Whittle BJ; Moncada S; Vane JR Prostaglandins; 1978 Sep; 16(3):373-88. PubMed ID: 364545 [TBL] [Abstract][Full Text] [Related]
8. Refractoriness of platelets to prostaglandins after infusion in rabbits. Bertelé V; Stemerman M; Schafer A; Adelman B; Smith M; Fuhro R; Salzman E J Lab Clin Med; 1985 Nov; 106(5):551-61. PubMed ID: 2997353 [TBL] [Abstract][Full Text] [Related]
9. Inhibition of prostaglandin E1-responsive platelet adenylate cyclase by heparin: a study of the mechanism of inhibition and its relevance to platelet aggregation. Amirrasooli H; Mac Neil S; Tomlinson S Br J Pharmacol; 1981 Jul; 73(3):639-47. PubMed ID: 7248663 [TBL] [Abstract][Full Text] [Related]
10. The binding of 6-oxo-prostaglandin E1 to platelet prostanoid receptors. Jaschonek K; Renn W; Weisenberger H Prostaglandins Leukot Med; 1986 Sep; 24(1):79-86. PubMed ID: 3020591 [TBL] [Abstract][Full Text] [Related]
11. Effects of PGI2 on platelet aggregation and adenylate cyclase activity in human type IIa hypercholesterolemia. Colli S; Lombroso M; Maderna P; Tremoli E; Nicosia S Biochem Pharmacol; 1983 Jul; 32(13):1989-93. PubMed ID: 6347202 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of prostaglandin D2 (PGD2) as an anticoagulative agent for haemodialysis in comparison with prostaglandin E1 (PGE1). Nakagawa S; Matsui N; Akiba T; Shinoda T; Fukudome Y; Ozawa K; Baba M; Nakanishi T; Takeuchi J Proc Eur Dial Transplant Assoc; 1981; 18():117-21. PubMed ID: 7036145 [TBL] [Abstract][Full Text] [Related]
13. Refractoriness of diabetic platelets to inhibitory prostaglandins. Lagarde M; Berciaud P; Burtin M; Dechavanne M Prostaglandins Med; 1981 Oct; 7(4):341-7. PubMed ID: 6273957 [TBL] [Abstract][Full Text] [Related]
14. Characterization of the platelet prostaglandin D2 receptor. Loss of prostaglandin D2 receptors in platelets of patients with myeloproliferative disorders. Cooper B; Ahern D J Clin Invest; 1979 Aug; 64(2):586-90. PubMed ID: 222813 [TBL] [Abstract][Full Text] [Related]
16. Stable 9 beta- or 11 alpha-halogen-15-cyclohexyl-prostaglandins with high affinity to the PGD2-receptor. Thierauch KH; Stürzebecher CS; Schillinger E; Rehwinkel H; Radüchel B; Skuballa W; Vorbrüggen H Prostaglandins; 1988 Jun; 35(6):855-68. PubMed ID: 2847246 [TBL] [Abstract][Full Text] [Related]
17. Effects of some naturally occurring prostaglandins of the D-, E-, and I-type and synthetic analogues on adenylate cyclase of human fat cell ghosts. Kather H; Simon B Res Exp Med (Berl); 1979 Oct; 176(1):25-9. PubMed ID: 392663 [TBL] [Abstract][Full Text] [Related]
18. Decreased number of PGD2 binding sites on platelets from patients with type IIa hyperlipoproteinemia. Abbate R; Modesti PA; Fortini A; Lombardi A; Matucci M; Gensini GF; Neri Serneri GG; Fellin R; Valerio G; Crepaldi G Atherosclerosis; 1985 Feb; 54(2):167-75. PubMed ID: 3857047 [TBL] [Abstract][Full Text] [Related]
19. Adenylate cyclase activation determines the effect of thromboxane synthase inhibitors on platelet aggregation in vitro. Comparison of platelets from responders and nonresponders. Gresele P; Blockmans D; Deckmyn H; Vermylen J J Pharmacol Exp Ther; 1988 Jul; 246(1):301-7. PubMed ID: 3134542 [TBL] [Abstract][Full Text] [Related]
20. Prostaglandin endoperoxide analogues which are both thromboxane receptor antagonists and prostacyclin mimetics. Armstrong RA; Jones RL; MacDermot J; Wilson NH Br J Pharmacol; 1986 Mar; 87(3):543-51. PubMed ID: 3026540 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]